01. Introduction: Managing the Nonhematological Adverse Effects of Clozapine

Learning Objectives:

After completing this activity, the learner will be able to:

1. Identify common adverse effects of clozapine
2. Implement management strategies for adverse effects of clozapine

Original Release Date: 04/01/2018

Expiration Date: 03/31/2022

Relevant Financial Disclosures: 

The following planners, faculty, and reviewers have the following relevant financial relationships with commercial interests to disclose:

Dr. Meyer has disclosed the following relationships:

• Acadia: Advisory committee, speaking
• Allergan: Advisory committee, speaking
• Alkermes: Advisory committee, speaking
• Intra-Cellular Therapies: Advisory committee
• Janssen Pharmaceutica: Speaking
• Merck: Speaking
• Neurocrine: Advisory committee, speaking
• Otsuka America, Inc.: Speaking
• Sunovion Pharmaceuticals: Speaking
• Acadia: Advisory board, speaking
• Allergan: Advisory board, speaking
• Alkermes: Advisory board, speaking
• Intra-cellular: Advisory board
• Janssen: Speaking
• Impel: Advisory board
• Otsuka: Speaking
• Neurocrine: Advisory board, speaking
• Sunovion: Speaking

All of the relevant financial relationships listed for these individuals have been mitigated.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com